<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Psychiatry</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3ABFFC06-5189-497E-9545-5C8507B9C212"><gtr:id>3ABFFC06-5189-497E-9545-5C8507B9C212</gtr:id><gtr:firstName>Amanda</gtr:firstName><gtr:otherNames>Jayne</gtr:otherNames><gtr:surname>Law</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G120%2F997"><gtr:id>10410A1D-86C6-4202-B5ED-34A1C2785A20</gtr:id><gtr:title>Neuregulin -1: dissecting the moleuclar mechanisms of genetic susceptibility for schizophrenia</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G120/997</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The rationale for this project comes from three lines of evidence (1) Neuregulin 1 (NRG1) has been robustly identified as a susceptibility gene for schizophrenia (2) Disease-associated polymorphisms in the NRG1 gene are primarily non-coding. Some of these variants may function by affecting the expression levels of the gene and the encoded protein (3) We have preliminary evidence of altered gene expression levels for an isoform of NRG1 in the brains of schizophrenic patients, postmortem. Moreover, these levels are associated with a disease-associated polymorphism in the gene. The aim of this proposal seeks to extend and fully elucidate these findings by using a translational approach combining human brain tissue, animal and in-vitro applications to fully determine the molecular underpinnings of NRG1 involvement in schizophrenia. The objectives include (1) identification of the specific isoform(s) of NRG1 involved in schizophrenia (2) determination of the biological role of such isoforms in cellular processes and brain development, in-vitro and in-vivo (3) functional analyses of disease-associated polymorphic regions of the NRG1 gene. In summary the project will (a) characterize changes in NRG1 expression in patients with schizophrenia and (b) determine the mechanistic basis of these changes, testing the hypothesis that genetic association of NRG1 with schizophrenia is mediated through abnormal splicing of the NRG1 gene. State-of-the-art molecular and immunochemical techniques will be used for the analyses of NRG1 expression in human postmortem brain tissue. Functional effects of candidate polymorphisms on gene expression will be investigated using in-vitro assays. The biological function of disease-associated isoform(s) will be investigated using transgenic animal models and in-vitro cell culture systems. Recent discoveries in the genetics of schizophrenia offer us an unprecedented opportunity for progress in reducing the burden of this illness. However, finding a gene is just a starting point and investigation of how the genes affect developing brain systems and relate to the pathogenesis of the disease is paramount. The proposed project is at the cutting edge of basic research in psychiatry. It will obtain valuable information on the nature of the abnormality of NRG1 in schizophrenia and may identify genetic targets and pathways that could be developed into strategies for prevention or treatment of the illness.</gtr:technicalSummary><gtr:fund><gtr:end>2009-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>535556</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5CB392BE-C738-46DA-8343-09761A99D69D</gtr:id><gtr:title>Molecular cloning of a brain-specific, developmentally regulated neuregulin 1 (NRG1) isoform and identification of a functional promoter variant associated with schizophrenia.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e43c51cbdfe577042672737ac316e0b7"><gtr:id>e43c51cbdfe577042672737ac316e0b7</gtr:id><gtr:otherNames>Tan W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>9FB4B689764</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>635FB3F0-970B-4456-93B0-B3CC4C9824FE</gtr:id><gtr:title>Molecular cloning and characterization of the human ErbB4 gene: identification of novel splice isoforms in the developing and adult brain.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e43c51cbdfe577042672737ac316e0b7"><gtr:id>e43c51cbdfe577042672737ac316e0b7</gtr:id><gtr:otherNames>Tan W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>nwTX7YrS9Lk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77793CE2-0614-415B-8936-B49BB77B7B50</gtr:id><gtr:title>Alpha7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic variation in neuregulin 1.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0fecf3486d4b5886709cb0051b5520b"><gtr:id>c0fecf3486d4b5886709cb0051b5520b</gtr:id><gtr:otherNames>Mathew SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>C9A57B956B3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E70D38F-F2D7-4C21-A327-409B9C0569A9</gtr:id><gtr:title>Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4193d0cb8049ecb7dfdd5e1fbecda86"><gtr:id>a4193d0cb8049ecb7dfdd5e1fbecda86</gtr:id><gtr:otherNames>Chong VZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn><gtr:outcomeId>1C2AE59C932</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7CE4A5C-899D-4D74-87A8-6D411A4186EB</gtr:id><gtr:title>A 5' promoter region SNP in NRG1 is associated with schizophrenia risk and type III isoform expression.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b39a0620d5b56288518163918969536"><gtr:id>7b39a0620d5b56288518163918969536</gtr:id><gtr:otherNames>Nicodemus KK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>16D63F92EF7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB6DCD62-FE5B-4265-BB6A-5C35BA8A00F9</gtr:id><gtr:title>Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f8b5a33b466464452fe54f1e5613608"><gtr:id>7f8b5a33b466464452fe54f1e5613608</gtr:id><gtr:otherNames>Law AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>F117CB093BC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CFF2B1A-C81E-4C7B-B35E-07E364CE8DEB</gtr:id><gtr:title>Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls.</gtr:title><gtr:parentPublicationTitle>Archives of general psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b39a0620d5b56288518163918969536"><gtr:id>7b39a0620d5b56288518163918969536</gtr:id><gtr:otherNames>Nicodemus KK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-990X</gtr:issn><gtr:outcomeId>Tja85MVE1gG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B347A3F5-5A0C-4D29-A205-D635D2368AAB</gtr:id><gtr:title>Common genetic variation in Neuregulin 3 (NRG3) influences risk for schizophrenia and impacts NRG3 expression in human brain.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ce6faace2874f531e9dbb7e187f7e98"><gtr:id>8ce6faace2874f531e9dbb7e187f7e98</gtr:id><gtr:otherNames>Kao WT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>hpZb4nE3abu</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G120/997</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>